Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 25 2023 - 4:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO SECTION 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2023
Commission File Number:
001-39950
Evaxion Biotech A/S
(Exact Name of Registrant as Specified
in Its Charter)
Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by
reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132)
and on Form F-1 (File No. 333-266050), including any prospectuses forming a part of such registration statements and to be a
part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
Evaxion Biotech A/S announces promising clinical Phase 1 data for
its personalized cancer vaccine EVX-01
Evaxion Biotech A/S (the “Company”), announced
promising clinical data from its EVX-01 Phase 1 clinical trial in metastatic melanoma. The Company will present the data on
June 3, 2023 at the 2023 ASCO annual meeting, in Chicago, Illinois.
On May 25, 2023 the Registrant issued a press release, a copy
of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Evaxion Biotech A/S |
| | |
Date: May 25, 2023 | By: | /s/
Bo Karmark |
| | Bo Karmark |
| | Chief Financial Officer |
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Evaxion Biotech AS (NASDAQ:EVAX)
Historical Stock Chart
From Jul 2023 to Jul 2024